Dajiang Yuan

Dajiang Yuan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JPJian Peng
Jian Peng
PLPingping Li
Pingping Li
YLYuan Li
Yuan Li
JQJichuan Quan
Jichuan Quan
YYYanwei Yao
Yanwei Yao
XWXiaoru Wang
Xiaoru Wang
Phosphofructokinase, platelet (PFKP) is a rate-limiting enzyme of glycolysis that plays a decisive role in various human physio-pathological processes. PFKP has been reported to have multiple functions in different cancer types, including lung cancer and breast cancer. However, no systematic pancancer analysis of PFKP has been performed; this type of analysis could elucidate the clinical value of PFKP in terms of diagnosis, prognosis, drug sensitivity, and immunological correlation. Systematic bioinformation analysis of PFKP was performed based on several public datasets, including The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), Genotype-Tissue Expression Project (GTEx), and Human Protein Atlas (HPA). Prospective carcinogenesis of PFKP across cancers was estimated by expression analysis, effect on patient prognosis, diagnosis significance evaluation, and immunity regulation estimation. Then, pancancer functional enrichment of PFKP was also assessed through its effect on the signaling score and gene expression profile. Finally, upstream expression regulation of PFKP was explored by promoter DNA methylation and transcription factor (TF) prediction. Our analysis revealed that high expression of PFKP was found in most cancer types. Additionally, a high level of PFKP displayed a significant correlation with poor prognosis in patients across cancers. The diagnostic value of PFKP was performed based on its positive correlation with programmed cell death-ligand 1 (PD-L1). We also found an obvious immune-regulating effect of PFKP in most cancer types. PFKP also had a strong negative correlation with several cancer drugs. Finally, ectopic expression of PFKP may depend on DNA methylation and several predicated transcription factors, including the KLF (KLF transcription factor) and Sp (Sp transcription factor) families. This pancancer analysis revealed that a high expression level of PFKP might be a useful biomarker and predictor in most cancer types. Additionally, the performance of PFKP across cancers also suggested its meaningful role in cancer immunity regulation, even in immunotherapy and drug resistance. Overall, PFKP might be explored as an auxiliary monitor for pancancer early prognosis and diagnosis.

29 June 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
SFShuaishuai Fan
Shuaishuai Fan
ZWZheng Wang
Zheng Wang
LZLi Zhao
Li Zhao
CZChenHui Zhao
ChenHui Zhao
DYDajiang Yuan
Dajiang Yuan
JWJingqi Wang
Jingqi Wang
Prostate cancer (PCa) is the second most common malignancy in men, but its exact pathogenetic mechanisms remain unclear. This study explores the effect of enhancer RNAs (eRNAs) in PCa. Firstly, we screened eRNAs and eRNA -driven genes from The Cancer Genome Atlas (TCGA) database, which are related to the disease-free survival (DFS) of PCa patients;. screening methods included bootstrapping, Kaplan–Meier (KM) survival analysis, and Pearson correlation analysis. Then, a risk score model was established using multivariate Cox analysis, and the results were validated in three independent cohorts. Finally, we explored the function of eRNA-driven genes through enrichment analysis and analyzed drug sensitivity on datasets from the Genomics of Drug Sensitivity in Cancer database. We constructed and validated a robust prognostic gene signature involving three eRNA-driven genes namely MAPK15, ZNF467, and MC1R. Moreover, we evaluated the function of eRNA-driven genes associated with tumor microenvironment (TME) and tumor mutational burden (TMB), and identified remarkable differences in drug sensitivity between high- and low-risk groups. This study identified a prognostic gene signature, which provides new insights into the role of eRNAs and eRNA-driven genes while assisting clinicians to determine the prognosis and appropriate treatment options for patients with PCa.

1 January 2020
Verified
Journal Article
Closed access
YLYanyan Li
Yanyan Li
DYDajiang Yuan
Dajiang Yuan
XLXiaoya Li
Xiaoya Li
SWShao Wang
Shao Wang


1 January 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
MWMei Wang
Mei Wang
TWTianqi Wang
Tianqi Wang
NWNan Wu
Nan Wu
YZYutao Zhang
Yutao Zhang
JJJindi Jia
Jindi Jia
DYDajiang Yuan
Dajiang Yuan
To investigate whether patient-controlled sedation (PCS) with remimazolam provides more precise sedation control and superior overall outcomes compared to conventional sedation (CS) in elderly patients undergoing lower limb surgery under spinal anesthesia. 120 patients aged ≥65 years (ASA physical status II~III) were randomized to receive either PCS (n=60) or CS (n=60). PCS received a loading dose (1 mg), background infusion (0.75 mg·h−1), and patient-demand boluses (0.5 mg; lockout interval 60s). CS received a loading dose (0.05~0.1 mg·kg−1) followed by a continuous infusion (0.1~0.3 mg·kg−1·h−1). The primary outcome was the proportion of patients who maintained optimal sedation, defined as a Ramsay Sedation Scale score of 3~4 with supportive bispectral index (BIS) monitoring. Secondary outcomes included onset/recovery time, hemodynamics, drug consumption, adverse events, and satisfaction. The proportion maintaining optimal sedation was higher in the PCS group (100% vs 88.3%, P < 0.05). PCS also showed lower total drug use, shorter recovery time (both P < 0.001), and higher scores for comfort, satisfaction, and cooperation (all P < 0.05). Hemodynamic stability was better in the PCS group, with higher mean arterial pressure at T2 through T6 timepoints (mean difference 4.5 mmHg, P = 0.019) and a lower hypotension incidence (10.0% vs 23.3%, P = 0.050). For elderly patients undergoing lower limb surgery under spinal anesthesia, patient-controlled sedation with remimazolam facilitates more precise sedation control. It ensures a higher proportion of optimal sedation depth while reducing drug consumption, accelerating recovery, and enhancing patient comfort and satisfaction. Under the conditions of this study, this approach constitutes a safe, effective, and individualized sedation strategy.